[Study on changes of plasma substance P in essential hypertension with left ventricular hypertrophy patients and the effect of promoting blood circulation and eliminating phlegm].
C Yan, Ming Gao, Zhouming Deng
Abstract
C Yan, Ming Gao, Zhouming Deng
Abstract
OBJECTIVE: Exploring the relationship between the plasma substance P(SP) and essential hypertension with left ventricular hypertrophy (EH-LVH) and the effect of promoting blood circulation and eliminating phlegm. METHODS: Before and after treatment, the changes of SP in patients wiith EH-LVH were measured by radioimmunoassay. Meanwhile, the changes of plasma renin activity (PRA), angiotension II (Ang II), left ventricular mass index (LVMI) and mean arterial pressure (MAP) were measured. RESULTS: The level of plasma SP in patients with EH-LVH was markedly lower than that of patients without EH-NLVH and healthy subjects (P < 0.001); the levels of PRA and Ang II were higher than those in control group (P < 0.01 or < 0.05). After treatment, the level of SP was significantly increased, while LVMI, MAP, PRA and Ang II were significantly decrease (P < 0.01 or < 0.05). The levels between SP and LVMI, MAP, PRA, Ang II were markedly negative correlated (P < 0.01) while levels between LVMI and PRA, Ang II were markedly positive correlated. CONCLUSIONS: The SP may be involved in the pathogenesis of EH-LVH; the mechanism of promoting blood circulation and eliminating phlegm reversing LVH might be related to its increasing the plasma SP.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
OBJECTIVE: Exploring the relationship between the plasma substance P(SP) and essential hypertension with left ventricular hypertrophy (EH-LVH) and the effect of promoting blood circulation and eliminating phlegm. METHODS: Before and after treatment, the changes of SP in patients wiith EH-LVH were measured by radioimmunoassay. Meanwhile, the changes of plasma renin activity (PRA), angiotension II (Ang II), left ventricular mass index (LVMI) and mean arterial pressure (MAP) were measured. RESULTS: The level of plasma SP in patients with EH-LVH was markedly lower than that of patients without EH-NLVH and healthy subjects (P < 0.001); the levels of PRA and Ang II were higher than those in control group (P < 0.01 or < 0.05). After treatment, the level of SP was significantly increased, while LVMI, MAP, PRA and Ang II were significantly decrease (P < 0.01 or < 0.05). The levels between SP and LVMI, MAP, PRA, Ang II were markedly negative correlated (P < 0.01) while levels between LVMI and PRA, Ang II were markedly positive correlated. CONCLUSIONS: The SP may be involved in the pathogenesis of EH-LVH; the mechanism of promoting blood circulation and eliminating phlegm reversing LVH might be related to its increasing the plasma SP.
Key concepts: Internal medicine, Left ventricular hypertrophy, Essential hypertension, Blood pressure, Plasma renin activity, Phlegm, Endocrinology, Medicine